ClinicalTrials.gg
Active, not recruitingNCT05197049GRAVITIUpdated Sep 25, 2026Results posted

A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease

A Phase 3 interventional study of Guselkumab Dose 1 and Guselkumab Dose 2 in Crohn Disease, sponsored by Janssen Research & Development, LLC. Active, not recruiting at 345 sites in 27 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Updated Sep 25, 20261 site added1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
350
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing guselkumab in Crohn Disease — 6 open to participants now, 11 under way, 7 of them phase 3. guselkumab · Crohn Disease.

Enrollment
4th of 13
350 · median 196
Started
2022
with 2 others
Phase 3
8 of 13
3 open now
Primary completion
2023-07
later than 0 of 10 live
Registered
3rd of 13
by date
Lead sponsor
8 of 13
Janssen Research & Development, LLC

Among the 13 studies testing guselkumab in Crohn Disease, this one is the 4th largest by enrollment, is one of 3 that started in 2022, is one of 8 in phase 3, reaches primary completion later than 0 of the 10 other live ones, and was the 3rd registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

6 of the 13 studies testing guselkumab in Crohn Disease are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About guselkumab

guselkumab: first FDA approval 2017 (TREMFYA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing guselkumab in Crohn Disease, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of guselkumab in participants with Crohn's disease.

03

Conditions studied

  • Crohn Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of Crohn's disease (CD) of at least 3 months in duration
  • Have moderate to severe CD as assessed by CDAI, stool frequency, and abdominal pain score, and Simple Endoscopic Score for Crohn's disease (SES-CD).
  • Demonstrated intolerance or inadequate response to conventional or to biologic therapy for CD

Exclusion criteria

Exclusion Criteria:

  • Current diagnosis of ulcerative colitis or indeterminate colitis
  • Complications of Crohn's disease that require surgical intervention or confound efficacy assessments
  • Unstable doses of concomitant Crohn's disease therapy
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
350 participants (actual)

Study arms

  • Experimental
    Group 1: Guselkumab

    Participants will receive guselkumab (Dose 1) injection subcutaneously followed by guselkumab (Dose 2) injection subcutaneously.

    Drug: Guselkumab Dose 1 · Drug: Guselkumab Dose 2

  • Experimental
    Group 2: Guselkumab

    Participants will receive guselkumab (Dose 1) injection subcutaneously followed by guselkumab (Dose 3) injection subcutaneously.

    Drug: Guselkumab Dose 1 · Drug: Guselkumab Dose 3

  • Placebo comparator
    Group 3: Placebo

    Participants will receive placebo injection subcutaneously.

    Drug: Placebo

Interventions

  • Guselkumab (Dose 1) will be administered by subcutaneous (SC) injection.

  • Guselkumab (Dose 2) will be administered by SC injection.

  • Guselkumab (Dose 3) will be administered by SC injection.

  • DrugPlacebo

    Placebo will be administered by SC injection.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieved Clinical Remission at Week 12

    Clinical remission was defined as a Crohn's Disease Activity Index (CDAI) score \<150. The multi-item CDAI score assessed severity of illness by collecting information on 8 different Crohn's disease-related variables (extraintestinal manifestations, abdominal mass, weight, hematocrit, use of antidiarrheal drug(s) and/or opiates, total number of liquid or very soft stools, abdominal pain/cramps, and general well-being). The last 3 variables were scored over 7 days by the participant on a diary card. The total CDAI score ranged from 0 (improvement in disease activity) to 600 (more disease activity) and a decrease in total CDAI score over time indicates improvement in disease activity.

    Time frame: At Week 12

  2. Percentage of Participants Who Achieved Endoscopic Response at Week 12

    Percentage of participants who achieved endoscopic response at Week 12 were reported. Endoscopic response was defined as greater than or equal to (\>=) 50 percent (%) improvement from baseline in the Simple Endoscopic Score for Crohn's Disease (SES-CD) score. SES-CD evaluated 4 endoscopic components (presence and size of ulcer, extent of ulcerated surface, extent of affected surface, and presence and type of narrowing) across 5 ileocolonic segments (ileum, right colon, transverse colon, left colon, and rectum), each scored from 0 (best) to 3 (worst) for each segment except narrowing component for which the maximum total score (that is, stricturing) was 11 points. The total SES-CD score was the sum of all the component scores across all the segments and it ranged from 0 (best) to 56 (worst), where higher scores indicated more severe disease.

    Time frame: At Week 12

Secondary outcomes

  1. Percentage of Participants Who Achieved Clinical Remission at Week 24

    Percentage of participants who achieved clinical remission at Week 24 were reported. Clinical remission was defined as a Crohn's Disease Activity Index (CDAI) score \<150. The multi-item CDAI score assessed severity of illness by collecting information on 8 different Crohn's disease-related variables (extraintestinal manifestations, abdominal mass, weight, hematocrit, use of antidiarrheal drug(s) and/or opiates, total number of liquid or very soft stools, abdominal pain/cramps, and general well-being). The last 3 variables were scored over 7 days by the participant on a diary card. The total CDAI score ranged from 0 (improvement in disease activity) to 600 (more disease activity) and a decrease in total CDAI score over time indicates improvement in disease activity.

    Time frame: At Week 24

  2. Percentage of Participants Who Achieved Patient-reported Outcome (PRO)-2 Remission at Week 12

    Percentage of participants who achieved PRO-2 remission at Week 12 were reported. PRO-2 remission was defined as an abdominal pain (AP) mean daily score \<=1, and stool frequency (SF) mean daily score \<=3, and no worsening of AP or SF from baseline. Mean daily AP score based on the CDAI was defined as the sum of abdominal pain/cramps ratings in the previous 7 days in a diary card divided by the total number of days assessments were performed. Average daily SF score based on the CDAI was defined as the sum of number of liquid or very soft stools in the previous 7 days in a diary card divided by the total number of days assessments were performed. Mean daily SF and AP scores at a scheduled visit were not calculated if total number of days of assessment was less than 5. Higher PRO-2 scores indicated more severe disease.

    Time frame: At Week 12

  3. Percentage of Participants Who Achieved Clinical Response at Week 12

    Clinical response was defined as a decrease from baseline in CDAI score \>= 100 points or CDAI score \< 150. The multi-item CDAI score assessed severity of illness by collecting information on 8 different Crohn's disease-related variables (extraintestinal manifestations, abdominal mass, weight, hematocrit, use of antidiarrheal drug(s) and/or opiates, total number of liquid or very soft stools, abdominal pain/cramps, and general well-being). The last 3 variables were scored over 7 days by the participant on a diary card. The total CDAI score ranged from 0 (improvement in disease activity) to 600 (more disease activity) and a decrease in total CDAI score over time indicates improvement in disease activity.

    Time frame: At Week 12

  4. Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) Through Week 48

    Percentage of participants with TEAEs through Week 48 were reported. An adverse event (AE) was any untoward medical occurrence in a clinical study participant participating in a clinical study and does not necessarily have a causal relationship with the study drug. An AE that occurred at or after the initial administration of study drug (Week 0) through data cutoff of Week 48 was considered treatment-emergent.

    Time frame: Placebo, Guselkumab 400 mg + 100 mg, and Guselkumab 400 mg + 200 mg: From Week 0 up to Week 48; Placebo arm subset - Rescue Treatment: From Week 16 up to Week 48

  5. Percentage of Participants With Treatment-Emergent Serious Adverse Events (TESAEs) Through Week 48

    Percentage of participants with TESAEs through Week 48 were reported. An SAE was any untoward medical occurrence in a clinical study participant resulting in any of the following outcomes or was deemed significant for any other reason: death, life-threatening (immediate risk of dying), initial or prolonged inpatient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect. An AE does not necessarily have a causal relationship with the study drug. Any SAE that occurred at or after the initial administration of study drug (Week 0) through the data cutoff of Week 48 was considered treatment-emergent.

    Time frame: Placebo, Guselkumab 400 mg + 100 mg, and Guselkumab 400 mg + 200 mg: From Week 0 up to Week 48; Placebo arm subset - Rescue Treatment: From Week 16 up to Week 48

  6. Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) Leading to Discontinuation of Study Drug Through Week 48

    Percentage of participants with TEAEs leading to discontinuation of study drug through Week 48 were reported. An adverse event (AE) was any untoward medical occurrence in a clinical study participant participating in a clinical study and does not necessarily have a causal relationship with the study drug. An AE that occurred at or after the initial administration of study drug (Week 0) through data cutoff of Week 48 was considered treatment-emergent.

    Time frame: Placebo, Guselkumab 400 mg + 100 mg, and Guselkumab 400 mg + 200 mg: From Week 0 up to Week 48; Placebo arm subset - Rescue Treatment: From Week 16 up to Week 48

07

Results

Posted Feb 21, 2025

Participant flow

Out of 350 participants randomized (1:1:1) to 1 of 3 treatments, 3 participants were excluded from all analysis sets due to non-compliance with Good Clinical Practice (GCP) guidance at 1 study site. Hence 347 participants were included in full analysis set. Study included a 24 week (wk) main treatment (12-wk induction followed by 12-wk maintenance) period followed by extension treatment period. In extension period, participants continued same maintenance dose regimen they received at Week 24.

Participant flow — Overall Study
MilestonePlaceboGuselkumab 400 mg + 100 mgGuselkumab 400 mg + 200 mg
Started118117115
Treated117115115
Participants who met at least 1 rescue criteria at week 16441414
Completed99110114
Not completed1971
Withdrew: Death010
Withdrew: Lost to follow-up310
Withdrew: Withdrawal by subject1531
Withdrew: Gcp non-compliance120

Outcome measures

PrimaryPercentage of Participants Who Achieved Clinical Remission at Week 12

Clinical remission was defined as a Crohn's Disease Activity Index (CDAI) score \<150. The multi-item CDAI score assessed severity of illness by collecting information on 8 different Crohn's disease-related variables (extraintestinal manifestations, abdominal mass, weight, hematocrit, use of antidiarrheal drug(s) and/or opiates, total number of liquid or very soft stools, abdominal pain/cramps, and general well-being). The last 3 variables were scored over 7 days by the participant on a diary card. The total CDAI score ranged from 0 (improvement in disease activity) to 600 (more disease activity) and a decrease in total CDAI score over time indicates improvement in disease activity.

Time frame:
At Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved Clinical Remission at Week 12
Percentage of participantsPlaceboCombined: Guselkumab 400 mg
Percentage of Participants Who Achieved Clinical Remission at Week 1221.4 (13.9 to 28.8)56.1 (49.7 to 62.5)
Statistical analysis
  • Placebo vs Combined: Guselkumab 400 mg · Mantel Haenszel · p = < 0.001 · Adjusted treatment difference:percentage: 34.9 · 95% CI 25.1 to 44.6Mantel-Haenszel stratum weights and the Sato variance estimator.
PrimaryPercentage of Participants Who Achieved Endoscopic Response at Week 12

Percentage of participants who achieved endoscopic response at Week 12 were reported. Endoscopic response was defined as greater than or equal to (\>=) 50 percent (%) improvement from baseline in the Simple Endoscopic Score for Crohn's Disease (SES-CD) score. SES-CD evaluated 4 endoscopic components (presence and size of ulcer, extent of ulcerated surface, extent of affected surface, and presence and type of narrowing) across 5 ileocolonic segments (ileum, right colon, transverse colon, left colon, and rectum), each scored from 0 (best) to 3 (worst) for each segment except narrowing component for which the maximum total score (that is, stricturing) was 11 points. The total SES-CD score was the sum of all the component scores across all the segments and it ranged from 0 (best) to 56 (worst), where higher scores indicated more severe disease.

Time frame:
At Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved Endoscopic Response at Week 12
Percentage of participantsPlaceboCombined: Guselkumab 400 mg
Percentage of Participants Who Achieved Endoscopic Response at Week 1221.4 (13.9 to 28.8)41.3 (34.9 to 47.7)
Statistical analysis
  • Placebo vs Combined: Guselkumab 400 mg · Mantel Haenszel · p = < 0.001 · Adjusted treatment difference:percentage: 19.9 · 95% CI 10.2 to 29.6Mantel-Haenszel stratum weights and the Sato variance estimator.
SecondaryPercentage of Participants Who Achieved Clinical Remission at Week 24

Percentage of participants who achieved clinical remission at Week 24 were reported. Clinical remission was defined as a Crohn's Disease Activity Index (CDAI) score \<150. The multi-item CDAI score assessed severity of illness by collecting information on 8 different Crohn's disease-related variables (extraintestinal manifestations, abdominal mass, weight, hematocrit, use of antidiarrheal drug(s) and/or opiates, total number of liquid or very soft stools, abdominal pain/cramps, and general well-being). The last 3 variables were scored over 7 days by the participant on a diary card. The total CDAI score ranged from 0 (improvement in disease activity) to 600 (more disease activity) and a decrease in total CDAI score over time indicates improvement in disease activity.

Time frame:
At Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved Clinical Remission at Week 24
Percentage of participantsPlaceboGuselkumab 400 mg + 100 mgGuselkumab 400 mg + 200 mg
Percentage of Participants Who Achieved Clinical Remission at Week 2421.4 (13.9 to 28.8)60.9 (51.9 to 69.8)58.3 (49.2 to 67.3)
Statistical analysis
  • Placebo vs Guselkumab 400 mg + 200 mg · Mantel Haenszel · p = < 0.001 · Adjusted treatment difference:percentage: 37.0 · 95% CI 25.6 to 48.4Mantel-Haenszel stratum weights and the Sato variance estimator.
  • Placebo vs Guselkumab 400 mg + 100 mg · Mantel Haenszel · p = < 0.001 · Adjusted treatment difference:percentage: 39.3 · 95% CI 28.0 to 50.7Mantel-Haenszel stratum weights and the Sato variance estimator.
SecondaryPercentage of Participants Who Achieved Patient-reported Outcome (PRO)-2 Remission at Week 12

Percentage of participants who achieved PRO-2 remission at Week 12 were reported. PRO-2 remission was defined as an abdominal pain (AP) mean daily score \<=1, and stool frequency (SF) mean daily score \<=3, and no worsening of AP or SF from baseline. Mean daily AP score based on the CDAI was defined as the sum of abdominal pain/cramps ratings in the previous 7 days in a diary card divided by the total number of days assessments were performed. Average daily SF score based on the CDAI was defined as the sum of number of liquid or very soft stools in the previous 7 days in a diary card divided by the total number of days assessments were performed. Mean daily SF and AP scores at a scheduled visit were not calculated if total number of days of assessment was less than 5. Higher PRO-2 scores indicated more severe disease.

Time frame:
At Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved Patient-reported Outcome (PRO)-2 Remission at Week 12
Percentage of participantsPlaceboCombined: Guselkumab 400 mg
Percentage of Participants Who Achieved Patient-reported Outcome (PRO)-2 Remission at Week 1217.1 (10.3 to 23.9)49.1 (42.7 to 55.6)
Statistical analysis
  • Placebo vs Combined: Guselkumab 400 mg · Mantel Haenszel · p = < 0.001 · Adjusted treatment difference:percentage: 32.1 · 95% CI 22.9 to 41.2Mantel-Haenszel stratum weights and the Sato variance estimator.
SecondaryPercentage of Participants Who Achieved Clinical Response at Week 12

Clinical response was defined as a decrease from baseline in CDAI score \>= 100 points or CDAI score \< 150. The multi-item CDAI score assessed severity of illness by collecting information on 8 different Crohn's disease-related variables (extraintestinal manifestations, abdominal mass, weight, hematocrit, use of antidiarrheal drug(s) and/or opiates, total number of liquid or very soft stools, abdominal pain/cramps, and general well-being). The last 3 variables were scored over 7 days by the participant on a diary card. The total CDAI score ranged from 0 (improvement in disease activity) to 600 (more disease activity) and a decrease in total CDAI score over time indicates improvement in disease activity.

Time frame:
At Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved Clinical Response at Week 12
Percentage of participantsPlaceboCombined: Guselkumab 400 mg
Percentage of Participants Who Achieved Clinical Response at Week 1233.3 (24.8 to 41.9)73.5 (67.8 to 79.2)
Statistical analysis
  • Placebo vs Combined: Guselkumab 400 mg · Mantel Haenszel · p = < 0.001 · Adjusted treatment difference:percentage: 40.3 · 95% CI 29.9 to 50.7Mantel-Haenszel stratum weights and the Sato variance estimator.
SecondaryPercentage of Participants With Treatment-Emergent Adverse Events (TEAEs) Through Week 48

Percentage of participants with TEAEs through Week 48 were reported. An adverse event (AE) was any untoward medical occurrence in a clinical study participant participating in a clinical study and does not necessarily have a causal relationship with the study drug. An AE that occurred at or after the initial administration of study drug (Week 0) through data cutoff of Week 48 was considered treatment-emergent.

Time frame:
Placebo, Guselkumab 400 mg + 100 mg, and Guselkumab 400 mg + 200 mg: From Week 0 up to Week 48; Placebo arm subset - Rescue Treatment: From Week 16 up to Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) Through Week 48
Percentage of participantsPlaceboGuselkumab 400 mg + 100 mgGuselkumab 400 mg + 200 mgPlacebo Arm Subset (Rescue Treatment): Placebo to Guselkumab
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) Through Week 4865.882.680.075.0
SecondaryPercentage of Participants With Treatment-Emergent Serious Adverse Events (TESAEs) Through Week 48

Percentage of participants with TESAEs through Week 48 were reported. An SAE was any untoward medical occurrence in a clinical study participant resulting in any of the following outcomes or was deemed significant for any other reason: death, life-threatening (immediate risk of dying), initial or prolonged inpatient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect. An AE does not necessarily have a causal relationship with the study drug. Any SAE that occurred at or after the initial administration of study drug (Week 0) through the data cutoff of Week 48 was considered treatment-emergent.

Time frame:
Placebo, Guselkumab 400 mg + 100 mg, and Guselkumab 400 mg + 200 mg: From Week 0 up to Week 48; Placebo arm subset - Rescue Treatment: From Week 16 up to Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants With Treatment-Emergent Serious Adverse Events (TESAEs) Through Week 48
Percentage of participantsPlaceboGuselkumab 400 mg + 100 mgGuselkumab 400 mg + 200 mgPlacebo Arm Subset (Rescue Treatment): Placebo to Guselkumab
Percentage of Participants With Treatment-Emergent Serious Adverse Events (TESAEs) Through Week 4813.713.07.82.3
SecondaryPercentage of Participants With Treatment-Emergent Adverse Events (TEAEs) Leading to Discontinuation of Study Drug Through Week 48

Percentage of participants with TEAEs leading to discontinuation of study drug through Week 48 were reported. An adverse event (AE) was any untoward medical occurrence in a clinical study participant participating in a clinical study and does not necessarily have a causal relationship with the study drug. An AE that occurred at or after the initial administration of study drug (Week 0) through data cutoff of Week 48 was considered treatment-emergent.

Time frame:
Placebo, Guselkumab 400 mg + 100 mg, and Guselkumab 400 mg + 200 mg: From Week 0 up to Week 48; Placebo arm subset - Rescue Treatment: From Week 16 up to Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) Leading to Discontinuation of Study Drug Through Week 48
Percentage of participantsPlaceboGuselkumab 400 mg + 100 mgGuselkumab 400 mg + 200 mgPlacebo Arm Subset (Rescue Treatment): Placebo to Guselkumab
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) Leading to Discontinuation of Study Drug Through Week 488.53.52.62.3

Adverse events

Collected over For arms Placebo, Guselkumab 400 mg + 100 mg, and Guselkumab 400 mg + 200 mg: From Week 0 up to Week 48; Placebo arm subset - Rescue Treatment: From Week 16 up to Week 48. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/117 (0%)16/117 (13.7%)57/117 (48.7%)
Placebo Arm Subset (Rescue Treatment): Placebo to Guselkumab0/44 (0%)1/44 (2.3%)19/44 (43.2%)
Guselkumab 400 mg + 100 mg1/115 (0.9%)15/115 (13%)65/115 (56.5%)
Guselkumab 400 mg + 200 mg0/115 (0%)9/115 (7.8%)68/115 (59.1%)
Most frequent serious events
Showing 10 of 37
Most frequent serious events
EventPlaceboPlacebo Arm Subset (Rescue Treatment): Placebo to GuselkumabGuselkumab 400 mg + 100 mgGuselkumab 400 mg + 200 mg
Crohn's DiseaseGastrointestinal disorders7/1170/441/1151/115
Anal AbscessInfections and infestations0/1171/440/1150/115
IleusGastrointestinal disorders0/1170/442/1150/115
Ventricular TachycardiaCardiac disorders0/1170/440/1151/115
KeratitisEye disorders0/1170/440/1151/115
Abdominal PainGastrointestinal disorders0/1170/441/1150/115
Anal FistulaGastrointestinal disorders0/1170/441/1150/115
GastritisGastrointestinal disorders0/1170/441/1151/115
Pancreatitis AcuteGastrointestinal disorders0/1170/440/1151/115
CholelithiasisHepatobiliary disorders0/1170/440/1151/115
Most frequent other events
Showing 10 of 21
Most frequent other events
EventPlaceboPlacebo Arm Subset (Rescue Treatment): Placebo to GuselkumabGuselkumab 400 mg + 100 mgGuselkumab 400 mg + 200 mg
Upper Respiratory Tract InfectionInfections and infestations12/1178/4415/11515/115
Crohn's DiseaseGastrointestinal disorders17/1173/448/1155/115
Abdominal PainGastrointestinal disorders7/1173/4410/11514/115
Covid-19Infections and infestations8/1171/4411/11511/115
HeadacheNervous system disorders5/1171/447/1159/115
AnaemiaBlood and lymphatic system disorders3/1170/448/1152/115
NasopharyngitisInfections and infestations6/1173/448/1150/115
PyrexiaGeneral disorders8/1172/443/1156/115
DiarrhoeaGastrointestinal disorders3/1170/446/1154/115
InfluenzaInfections and infestations5/1171/446/1156/115

Baseline characteristics

Baseline characteristics data were presented for full analysis set (FAS) which included all randomized participants who received at least 1 dose of study intervention.

Age, Categorical
Age, Categorical(Participants)PlaceboGuselkumab 400 mg + 100 mgGuselkumab 400 mg + 200 mgTotal
<=18 years0000
Between 18 and 65 years114113111338
>=65 years3249
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboGuselkumab 400 mg + 100 mgGuselkumab 400 mg + 200 mgTotal
Female504945144
Male676670203
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboGuselkumab 400 mg + 100 mgGuselkumab 400 mg + 200 mgTotal
Hispanic or Latino910827
Not Hispanic or Latino939498285
Unknown or Not Reported1511935
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboGuselkumab 400 mg + 100 mgGuselkumab 400 mg + 200 mgTotal
American Indian or Alaska Native0000
Asian28262276
Native Hawaiian or Other Pacific Islander0000
Black or African American5049
White717979229
More than one race0000
Unknown or Not Reported13101033
Region of Enrollment
Region of Enrollment(Participants)PlaceboGuselkumab 400 mg + 100 mgGuselkumab 400 mg + 200 mgTotal
BELGIUM1012
Bosnia34411
BRAZIL1312732
CHINA19161651
CROATIA0123
CZECH REPUBLIC57214
FRANCE53311
GERMANY48113
HUNGARY43310
ISRAEL0011
ITALY0112
JAPAN5106
JORDAN158932
LITHUANIA1023
MALAYSIA0123
NEW ZEALAND0112
POLAND27283388
SLOVAKIA1449
SOUTH KOREA26311
SPAIN1315
TAIWAN2013
TURKEY1315
UNITED STATES851730
AgeContinuous
AgeContinuous(years)PlaceboGuselkumab 400 mg + 100 mgGuselkumab 400 mg + 200 mgTotal
Mean36 ± 12.7137.4 ± 13.3239.1 ± 12.5637.5 ± 12.89
08

Study locations

345 sites

Showing the first 100 of 345 sites across 27 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Hart A, Panaccione R, Steinwurz F, Danese S, Hisamatsu T, Cao Q, Ritter T, Seidler U, Olurinde M, Vetter ML, Yee J, Yang Z, Wang Y, Johanns J, Han C, Sahoo A, Terry NA, Sands BE, D'Haens G; GRAVITI Study Group. Efficacy and Safety of Guselkumab Subcutaneous Induction and Maintenance in Participants With Moderately to Severely Active Crohn's Disease: Results From the Phase 3 GRAVITI Study. Gastroenterology. 2025 Aug;169(2):308-325. doi: 10.1053/j.gastro.2025.02.033. Epub 2025 Mar 18. PubMed 40113101 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.janssen.com

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2022 to primary completion in Jul 2023, 17 months.

Results were first posted in Feb 2025, 1 year 7 months after primary completion. A results delay was requested in Jul 2024.

Of 70 industry-sponsored phase 3 interventional studies under Crohn Disease, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 69. This study's 17 months is below that.

Counting every sponsor, half of 88 studies reached it within 49 months; a quarter within 36 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2022
First posted
Jan 19, 2022
StartActual
Jan 19, 2022
Primary completionActual
Jul 4, 2023
CompletionEst.
Oct 30, 2028
Results delay requested
Jul 1, 2024
Results first posted
Feb 21, 2025
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Centrum Medyczne Melita Medical 2 · Wroclaw, Poland
Show 1 removed
  • Centrum Medyczne Melita Medical · Wroclaw, Poland
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    1 site added, 1 site removed
    Show site
    • Centrum Medyczne Melita Medical 2 · Wroclaw, Poland
    Show 1 removed
    • Centrum Medyczne Melita Medical · Wroclaw, Poland
    + 2 other changes: verification date and registry notes

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05197049
Responsible party
Sponsor
First posted
Jan 19, 2022
Start date
Jan 19, 2022
Primary completion
Jul 4, 2023
Completion
Oct 30, 2028 (estimated)
Results posted
Feb 21, 2025
Last update
Sep 25, 2026

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Guselkumab

Start the discussion